Prevalence of Factor V Leiden in Patients with Myocardial Infarction and Normal Coronary Angiography

Jacques Mansourati; Antoine Da Costa; Stéphane Munier; Bernard Mercier; Brigitte Tardy; Claude Ferec; Karl Isaaz; Jean-Jacques Blanc

doi:10.1055/s-0037-1613927

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 83(06): 822-825
DOI: 10.1055/s-0037-1613927

Commentary

Schattauer GmbH

Prevalence of Factor V Leiden in Patients with Myocardial Infarction and Normal Coronary Angiography

Jacques Mansourati

¹From the Cardiology Departments of Brest

,

Antoine Da Costa

²North Hospital of Saint-Etienne

,

Stéphane Munier

¹From the Cardiology Departments of Brest

,

Bernard Mercier

³the Human Genetics Laboratory of Brest

,

Brigitte Tardy

⁴Department of Hematology, North Hospital of Saint Etienne, France

,

Claude Ferec

³the Human Genetics Laboratory of Brest

,

Karl Isaaz

²North Hospital of Saint-Etienne

,

Jean-Jacques Blanc

¹From the Cardiology Departments of Brest

› Author Affiliations

Abstract

Summary

Factor V Leiden is associated with an increased risk of venous thrombosis and myocardial infarction in young women, but not in men in this latter case. The aim of this study was to evaluate the prevalence of this mutation in patients with myocardial infarction but normal coronary angiography.

We compared 3 groups of patients: one group consisted of 107 patients with premature myocardial infarction but no significant coronary artery stenosis; another group of 244 patients with myocardial infarction and significant coronary artery stenosis; a third group of 400 healthy controls.

Factor V Leiden was found in 13 patients (12.1%) who had a myocardial infarction without significant coronary artery stenosis, 11 patients (4.5%) who had a myocardial infarction with significant coronary artery stenosis (p = 0.01) and in 20 controls (5%) (p = 0.01). Odds ratio associated with factor V Leiden were respectively 2.93 (CI95 : 1.18-7.31) and 2.63 (CI95 : 1.19-5.78) when we compared myocardial infarction patients without significant coronary artery stenosis to controls or to patients with significant coronary artery stenosis.

In myocardial infarction patients without significant coronary artery stenosis, prevalence of factor V Leiden is significantly higher than in controls. This new finding supports the hypothesis that thrombosis plays a key role in this selected situation.

Keywords

Coagulation - myocardial infarction - thrombosis - genetics

Full Text

References

References
1 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-400.
2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3 Dahlbäck B. Resistance to activated protein C, the Arg 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Haemost 1995; 73: 739-42.
4 Svensson PJ, Dalhbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
5 Dahlbäck B. Physiological anticoagulation. Inherited resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
6 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-7.
7 Emmerich J, Poirier O, Evans A, Marques PVidal, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction Arg 506 to Gln factor V mutation and activated protein C resistance. Lancet 1995; 345: 321.
8 Ridker PM, Hennekens C, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stoke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
9 Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506 →→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75: 701-2.
10 Redondo M, Watzke HH, Stuscki B, Sulzer I, Demarmels FBiasiutti, Binder BR, Furlan M, Lämmle B, Wuillemin WA. Coagulation factors II, V, VII, and X, prothrombin gene 20210GA transition, and factor V Leiden in coronary artery disease. High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
11 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
12 Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HV. Advantages and applications of the centerline method for charecterizing regional ventricular function. Circulation 1986; 74: 293-305.
13 Bertrand ME, Rousseau MF, LaBlanche JM, Warembourg Jr H, Carre AG, Lekieffre JP. La détection du spasme des artères coronaires par le test à le méthylergométrine. Technique. Résultats. Indications. Arch Mal Cœur 1979; 42: 123-6.
14 Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point mutation at ARG 506 of factor V. Lancet 1994; 343: 1535-6.
15 Alhenc-Gelos M, Gandrille S, Aubry ML, Emmerich J, Flessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-6.
16 Welch CC, Proudfit WC, Sones FM. Cinecoronary arteriography in young men. Circulation 1970; 42: 647.
17 Campeau L. Myocardial infarction with normal selective coronary. arteriograms. sAm Heart J 1970; 79: 139-41.
18 Cheng TO, Bashour T, Singh BK, Kelser GA. Myocardial infarction in the absence of coronary arteriosclerosis. Results of coronary spasm (?). Am J Cardiol 1972; 30: 680-2.
19 Bory M, Benichou M, Djiane P, Serradimigni A. Devenir de l’angor spastique à coronaires normales ou peu altérées. Nouv Presse Med 1982; 29: 2195-9.
20 Lindsay J, Dwyer S, Punja U. Angiographic demonstration of coronary occlusion during spontaneous acute myocardial infarction and subsequent angiographically normal coronary arteries. Am J Cardiol 1983; 05: 1227-8.
21 Monassier JP, Coulbois PM, Valeix B, Hanssen M, Touhami L, Schaaf R. Infarctus du myocarde par thrombose aigue coronarienne droite. Arch Mal Coeur 1982; 15: 1425-30.
22 Anderson JL, Marshall HM, White RS, Datz F. Streptokinase thrombolysis for acute myocardial infarction in young adults with normal coronary arteries. Am Heart J 1983; 106: 1437-8.
23 Gertz SD, Pasternak RC, Gotsman MS, Blaumanis OR, Nelson E. Myocardial infarction with normal coronaries. Circulation 1977; 56: 128-9.
24 Gertz SD, Uretsky G, Wajnberg RS, Navot N, Gotsman MS. Endothelial cell damage and thrombus formation after partial arterial constriction: relevance to the role of coronary artery spasm in the pathogenesis of myocardial infarction. Circulation 1981; 63: 476-86.
25 Boschat J, Matteodo K, Gilard M, Larlet JM, Provost K, Jobic Y, Guillo P, Etienne Y, Mansourati J, Blanc JJ. Echographie endocoronaire et coronarographie quantitative. Corrélations avant et après angioplastie transluminale coronaire. Arch Mal Cœur 1997; 90: 353-60.
26 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
27 Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.